12-week Open-label Evaluation of Efficacy and Safety of Indacaterol

NCT01232894 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: Indacaterol
DRUG: Long-acting beta2-agonist

Sponsor

Novartis Pharmaceuticals